No abstract available
MeSH terms
-
Adverse Drug Reaction Reporting Systems
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Cardiovascular Diseases / chemically induced*
-
Celecoxib
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / adverse effects*
-
Cyclooxygenase Inhibitors / pharmacology
-
Drug Approval*
-
Drug Industry
-
Epoprostenol / antagonists & inhibitors
-
Gastrointestinal Diseases / chemically induced
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / metabolism
-
Isoxazoles / adverse effects
-
Lactones / adverse effects*
-
Lactones / pharmacology
-
Membrane Proteins
-
Naproxen / adverse effects
-
Prostaglandin-Endoperoxide Synthases / metabolism
-
Pyrazoles
-
Risk
-
Sulfonamides / adverse effects
-
Sulfonamides / pharmacology
-
Sulfones
-
Thromboxane A2 / biosynthesis
-
United States
-
United States Food and Drug Administration
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Isoxazoles
-
Lactones
-
Membrane Proteins
-
Pyrazoles
-
Sulfonamides
-
Sulfones
-
rofecoxib
-
valdecoxib
-
Thromboxane A2
-
Naproxen
-
Epoprostenol
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Celecoxib